Impax threatened to launch at risk

Drugmaker Impax said it could have marketed a generic version of Opana ER – even with the possibility of a patent infringement suit – before ultimately agreeing to be paid $112 million in 2010 to end ongoing litigation.

Unlock unlimited access to all Global Competition Review content